Comparative Pharmacology
Head-to-head clinical analysis: TRIGLIDE versus TRILIPIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIGLIDE versus TRILIPIX.
TRIGLIDE vs TRILIPIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIGLIDE (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) activator. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.
TRILIPIX (fenofibric acid) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apoprotein C-III.
Initial dose: 60 mg (1 tablet) twice daily, gradually increased over 3-7 days to maintenance dose of 120 mg twice daily.
135 mg orally once daily, not to exceed 135 mg/day.
None Documented
None Documented
22-35 hours; prolonged in renal impairment (up to 50 hours).
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 10-35 hours), allowing once-daily dosing.
Primarily renal (70% as unchanged drug), 20% fecal, <10% biliary.
Primarily renal excretion as glucuronide conjugate and unchanged drug; ~60% of dose excreted in urine as fenofibric acid and its glucuronide, ~25% in feces.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic